Last reviewed · How we verify

NCT05834621

AMNIOmics: A Prenatal Rapid Genome Validation Study

Withdrawn Last updated 5 September 2025
What this trial tests

trial in Multiple Anomalies of Fetus. Withdrawn.

Timeline
7 January 2025
Primary endpoint
7 January 2025
7 January 2025

Quick facts

Lead sponsorMayo Clinic
StatusWithdrawn
Study typeOBSERVATIONAL
Start date7 January 2025
Primary completion7 January 2025
Estimated completion7 January 2025

Conditions studied

Sponsor

Mayo Clinic

Who can join

Eligibility, any sex, with Multiple Anomalies of Fetus or Genetic Predisposition Suspected. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to validate Whole Genome Sequencing (WGS) on amniotic fluid to reduce the time to diagnosis and enhance the care for the fetus/neonate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05834621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing